In the BioHarmony Drug Report Database
Prednisolone tebutate
Hydeltra-tba (prednisolone tebutate) is a small molecule pharmaceutical. Prednisolone tebutate was first approved as Hydeltra-tba on 1982-01-01. It is used to treat adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, and berylliosis amongst others in the USA.
Trade Name
|
Hydeltra-tba |
|---|---|
Common Name
|
prednisolone tebutate |
ChEMBL ID
|
CHEMBL1200909 |
Indication
|
adrenal insufficiency, ankylosing spondylitis, asthma, atopic dermatitis, berylliosis, brain neoplasms, collagen diseases, conjunctivitis, dermatitis herpetiformis, edema, erythema multiforme, hemolytic anemia, hypercalcemia, inflammation, leukemia, multiple sclerosis, mycosis fungoides, nephrotic syndrome, pemphigus, pulmonary tuberculosis, rheumatic diseases, sarcoidosis, serum sickness, synovitis, systemic lupus erythematosus, thrombocytopenia, thyroiditis, ulcerative colitis, uveitis |
Drug Class
|
Prednisone and prednisolone derivatives |
Image (chem structure or protein)